| Revenue growth | 12.9% YoY for Q1 FY27 |
|---|---|
| Margins | EBITDA margin improved 250 bps YoY to 26.3%. |
| Demand visibility | Strong recovery in acute; double-digit growth in Mankind and BSV businesses. |
| Management confidence | High, citing disciplined execution and strengthening business fundamentals. |
Growth
Revenue reached INR 4,031 Cr (+12.9% YoY); EBITDA at INR 1,060 Cr (+24.7% YoY) with 26.3% margin.
Outlook
Focused on increasing chronic share (currently 39.6%) and integrating BSV specialty business for long-term sustainable growth.
Risks
Softness in consumer healthcare growth (4% YoY) due to discontinued cash and carry business base effect.
Last quarter's promises, checked
Delivered
- Guided 25-26% EBITDA margin → delivered 26.3% (= BEAT)
- Guided double-digit domestic growth → delivered 12.9% (= BEAT)
- Guided high-teens/20% exports growth → delivered 29% (= BEAT)
Partly delivered
- Guided 39% chronic share → delivered 39.6% (= PARTIAL)
Missed
- Guided double-digit consumer growth → delivered 4% (= MISS)
Investor Presentation filed with NSE, NSE: MANKIND. Summary written with AI assistance from the document.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,496.30
- Market cap
- ₹1,03,108 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 50.5×Sector 47.4×
- Promoter holding
- 72.63%-0.03% QoQ
- FII holding
- 9.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Annual General Meeting
Mankind Pharma announced the successful passing of a special resolution to appoint Mr. Anish Vanraj Bafna as a Non-Executive Independent Director. The Postal Ballot concluded with the required majority.
Mankind Pharma Other Announcement
Mankind Pharma has been assigned an ESG rating of 68.21 ('Leader' category) by Niche99 ESG Ratings, based on publicly available data for FY 2025-26.
Mankind Pharma Merger & Restructuring
Mankind Pharma announced that members of its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), approved its voluntary liquidation in an EGM.
Mankind Pharma Employee Stock Options
Mankind Pharma has allotted 49,112 equity shares under its ESOP Plan 2022 to eligible employees upon exercise of options. The allotment increases its paid-up share capital.
- Value
- ₹4.22 Cr
Mankind Pharma Employee Stock Options
Mankind Pharma has allotted 49,112 equity shares under its ESOP scheme. This allotment increases the paid-up share capital by Rs. 49,112 in face value.
Mankind Pharma Management Change
Mankind Pharma announced the cessation of Mr. Bharat Anand as an Independent Director, effective August 30, 2026, upon the completion of his second term.